Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina
- Authors
- Kang, Hyun-Jae; Oh, Il-Young; Chung, Jin-Wook; Yang, Han-Mo; Suh, Jung-Won; Park, Kyung Woo; Kwon, Taek Keun; Lee, Hae-Young; Cho, Young-Seok; Youn, Tae-Jin; Koo, Bon-Kwon; Kang, Won-Yu; Kim, Weon; Rha, Seung-Woon; Bae, Jang Ho; Chae, In-Ho; Choi, Dong-Ju; Kim, Hyo-Soo
- Issue Date
- 11월-2012
- Publisher
- OXFORD UNIV PRESS
- Keywords
- Celecoxib; Drug-eluting stent; Stent thrombosis
- Citation
- EUROPEAN HEART JOURNAL, v.33, no.21, pp.2653 - 2661
- Indexed
- SCIE
SCOPUS
- Journal Title
- EUROPEAN HEART JOURNAL
- Volume
- 33
- Number
- 21
- Start Page
- 2653
- End Page
- 2661
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/107166
- DOI
- 10.1093/eurheartj/ehs001
- ISSN
- 0195-668X
- Abstract
- Aims In the previous COREA-TAXUS trial, a 6-month adjunctive use of celecoxib reduced target-lesion revascularization (TLR) without increased thrombotic risk. We aimed to confirm the effects of 3-month celecoxib in patients receiving drug-eluting stent (DES) implantation in the larger prospective, randomized trial. Methods and results Patients (n = 909) treated for native coronary lesions were randomized into four groups: the control or the celecoxib group with stratification by stents: paclitaxel-eluting stent (PES) or zotarolimus-eluting stent (ZES). In the celecoxib group, 200 mg of celecoxib was given twice daily for 3 months after the procedure. The primary endpoint was in-stent late loss (LL) at 6 months. In-stent LL was significantly lower in the celecoxib group than the control group (0.64 +/- 0.54 vs. 0.55 +/- 0.47 mm, P = 0.02). The trend of LL reduction in the celecoxib group was maintained in the ZES and PES subgroups, although it did not reach statistical significance. There was a trend towards the reduced clinically driven TLR in the celecoxib group (5.7 vs. 3.2, log-rank P = 0.09), but adverse cardiac events rate did not differ between the two groups (composite of cardiac death, non-fatal myocardial infarction, and TLR; 8.6 vs. 7.7, log-rank P = 0.84). Non-fatal myocardial infarction and cardiac death occurred in 1.6 of the patients in the celecoxib group when compared with 0.2 in the control group (log-rank P = 0.03). Conclusion Three-month adjunctive celecoxib would be useful to reduce LL of DES. However, this study may raise the concern about increased thrombotic risk with celecoxib even in patients receiving dual anti-platelet therapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.